List of Excipients in Branded Drug ROCURONIUM BROMIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
B Braun Medical Inc	ROCURONIUM BROMIDE	rocuronium bromide	0264-5711	GLUCONOLACTONE
B Braun Medical Inc	ROCURONIUM BROMIDE	rocuronium bromide	0264-5711	SODIUM ACETATE
B Braun Medical Inc	ROCURONIUM BROMIDE	rocuronium bromide	0264-5711	SODIUM CITRATE
B Braun Medical Inc	ROCURONIUM BROMIDE	rocuronium bromide	0264-5711	WATER

Generic Drugs Containing ROCURONIUM BROMIDE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	rocuronium bromide	0143-9250	ACETIC ACID
Hikma Pharmaceuticals USA Inc	rocuronium bromide	0143-9250	SODIUM ACETATE
Hikma Pharmaceuticals USA Inc	rocuronium bromide	0143-9250	SODIUM CHLORIDE
Hikma Pharmaceuticals USA Inc	rocuronium bromide	0143-9250	SODIUM HYDROXIDE
Hikma Pharmaceuticals USA Inc	rocuronium bromide	0143-9250	WATER
Hospira Inc	rocuronium bromide	0409-1403	ACETIC ACID

What are the Most Frequently-Used Excipients in ROCURONIUM BROMIDE?

# Of NDCs	Excipient
44	ACETIC ACID
5	NITROGEN
44	SODIUM ACETATE
44	SODIUM CHLORIDE
44	SODIUM HYDROXIDE
15	WATER

Last updated: August 14, 2026

Rocuronium bromide is an established generic neuromuscular blocking agent with limited active-ingredient patent protection and high formulation substitutability. The commercial opportunity is concentrated in sterile-product execution: ready-to-use presentations, room-temperature stability, supply reliability, preservative-free packaging, and differentiated hospital logistics. Excipient innovation can support formulation patents and regulatory differentiation, but it is unlikely to create broad market exclusivity without a meaningful improvement in stability, usability, or administration safety.

Rocuronium Bromide Excipient Strategy and Commercial Opportunities

What is the FDA regulatory status of rocuronium bromide?

Rocuronium bromide is an FDA-approved small-molecule nondepolarizing neuromuscular blocking agent used to facilitate tracheal intubation and provide skeletal-muscle relaxation during surgery or mechanical ventilation. The reference product is Zemuron, originally approved under NDA 019857. Generic rocuronium bromide injections are approved through the abbreviated new drug application pathway.[1]

Attribute	Commercial status
Active ingredient	Rocuronium bromide
Therapeutic class	Aminosteroidal neuromuscular blocker
Primary route	Intravenous
Common concentration	10 mg/mL
Typical dosage forms	Single-dose vials, multiple-dose or pharmacy-stock presentations depending on product
FDA pathway	NDA reference product and ANDA generic products
Biosimilar classification	Not applicable; rocuronium is a small molecule
Main purchasers	Hospitals, ambulatory surgery centers, emergency departments, anesthesia providers
Main commercial constraints	Sterile manufacturing, cold-chain management, shortage prevention, container-closure performance

Rocuronium is administered intravenously and has no practical oral dosage-form opportunity. The relevant formulation platform is therefore a sterile aqueous injection with controlled pH, acceptable osmolality, chemical stability, low particulate burden, and reliable compatibility with syringes, infusion systems, and intravenous lines.

What excipients are used in rocuronium bromide injection?

Reference and generic products generally use a simple aqueous system containing rocuronium bromide, water for injection, and pH-adjusting or buffering components. Product labels identify sodium acetate and acetic acid in the reference formulation; exact inactive-ingredient composition can vary among manufacturers.[1,2]

Excipient function	Common approach in rocuronium injection	Commercial purpose
Vehicle	Water for injection	Dissolves active ingredient and supports intravenous administration
Buffer or pH modifier	Acetate system, including sodium acetate and acetic acid	Controls pH during manufacture and storage
Tonicity adjustment	May be achieved through formulation composition or additional salts, depending on product	Supports intravenous tolerability
Antimicrobial preservation	Generally avoided in single-dose presentations	Reduces preservative exposure and simplifies hospital use
Chelation	Not a standard label-defining component	Could be evaluated only if metal-catalyzed degradation is demonstrated
Surfactant	Not generally required in a simple aqueous formulation	May create new extractables, compatibility, or safety issues

The formulation target is usually an acidic aqueous solution. The reference labeling identifies a pH range of approximately 3.8 to 4.2 and refrigerated storage requirements, with permitted room-temperature exposure under defined conditions.[1]

The limited excipient profile is commercially important. A competitor does not need to reproduce the reference formulation exactly if the finished product meets applicable quality, bioequivalence, stability, sterility, and labeling requirements. That creates room for formulation optimization but also limits the defensibility of minor excipient changes.

How should an excipient strategy for rocuronium bromide be designed?

The strongest strategy is to treat excipients as part of a sterile-product operating system rather than as a standalone formulation innovation.

1. Optimize pH control

The acetate buffer system should be evaluated across the full manufacturing and storage range. Key studies should measure:

• Rocuronium assay and degradation products
• pH drift after terminal sterilization or aseptic processing
• Subvisible and visible particles
• Color and clarity
• Container-closure interaction
• Compatibility after dilution in commonly used infusion fluids

A low-buffer-capacity formulation may reduce total excipient load but can permit pH movement during storage. A higher buffer capacity can improve robustness but may increase osmolality or create a less flexible formulation during dilution.

2. Control osmolality without unnecessary salts

Intravenous products used in anesthesia should avoid avoidable tonicity excursions. Sodium chloride or other tonicity agents may be appropriate in a particular formulation, but adding them without a demonstrated need can increase ionic strength and raise compatibility questions.

The commercial objective is a formulation that remains well tolerated while minimizing the number of excipients, reducing raw-material qualification requirements, and simplifying global regulatory filings.

3. Evaluate preservative-free packaging

Preservative-free single-dose vials are attractive for operating rooms and anesthesia carts. They reduce concerns about repeated-dose contamination and preservative exposure. A preservative-free design also aligns with a simple generic formulation and avoids the need to justify preservative safety across neonatal, pediatric, and critically ill populations.

The tradeoff is packaging cost and inventory handling. A multi-dose presentation could reduce packaging expense but would require stronger antimicrobial-preservation justification and a different in-use stability profile.

4. Select container materials early

Rocuronium products should be evaluated in:

• Type I glass vials
• Polymer vials or ampoules
• Prefilled syringes
• Ready-to-use infusion bags
• Plastic IV containers

Studies should assess adsorption, leachables, extractables, stopper compatibility, silicone oil exposure, and performance after agitation or transport. A formulation that is stable in glass may behave differently in polymer systems or prefilled syringes.

Container-closure selection is one of the more defensible areas for product differentiation because it affects hospital workflow, breakage risk, waste, and supply-chain resilience.

What formulation patents could protect rocuronium bromide products?

Formulation patents could cover a defined combination of rocuronium bromide, buffer components, pH range, concentration, container, or storage condition. The strongest claims would require a measurable technical result, such as:

• Extended room-temperature stability
• Reduced degradation during transport
• Improved compatibility with a polymer syringe
• Reduced particulate formation
• Improved recovery from a container
• Longer in-use stability after dilution
• Reduced administration errors through a standardized presentation

A patent directed only to the use of sodium acetate and acetic acid in an aqueous rocuronium solution would likely face significant validity and obviousness pressure because the reference formulation and ordinary sterile-injection practices are publicly known.[1,3]

Commercially useful claims would need to connect the excipient selection to unexpected stability or usability results. Broad claims covering routine pH adjustment, standard buffers, or conventional vial packaging would be vulnerable to prior-art challenges.

When does rocuronium bromide lose exclusivity?

Rocuronium bromide has already moved beyond the principal small-molecule exclusivity period. The reference product was approved in the 1990s, and generic products are commercially established. The relevant question is not when the active ingredient loses exclusivity, but whether a particular supplier has a surviving formulation, manufacturing, or presentation right.

Exclusivity category	Assessment
New chemical entity exclusivity	Expired
Reference-product market exclusivity	Expired
Active-ingredient patent barrier	No longer the primary commercial barrier
Formulation patents	Possible, but generally narrow and product-specific
Method-of-use patents	Limited practical significance for a mature hospital injectable
Regulatory exclusivity for generics	Depends on individual ANDA approvals and any applicable competitive provisions
Orphan-drug exclusivity	Not applicable to the standard rocuronium indication

The FDA Orange Book remains the principal source for listed patents and regulatory exclusivity associated with approved products.[4] For a mature generic injectable, Orange Book entries are less likely to determine market access than manufacturing capacity, injectable quality history, and hospital contracting.

What is the Orange Book status of rocuronium bromide?

Rocuronium bromide products are generally commercialized as generic injectable products linked to the reference NDA. The Orange Book identifies approved products, reference-listed drug relationships, patents listed by sponsors, and applicable exclusivity periods.[4]

The commercial review should distinguish between:

1. Patents listed for the reference product.
2. Patents listed for a specific approved generic presentation.
3. Unlisted formulation or manufacturing patents.
4. Patents that have expired, been delisted, or are not enforceable against a particular ANDA pathway.

An Orange Book listing does not by itself establish that a patent will block generic entry. Patent scope, expiration, certification strategy, and litigation history determine practical relevance.

Which companies are challenging rocuronium bromide exclusivity?

The market is already characterized by generic competition rather than by a single active Paragraph IV campaign. Generic suppliers compete through ANDA approvals, manufacturing reliability, vial sizes, contract pricing, and hospital distribution.

Paragraph IV certification remains legally available when an ANDA applicant disputes a listed patent. For rocuronium bromide, the commercial importance of a new Paragraph IV challenge would depend on whether a currently enforceable patent covers a commercially important formulation or delivery system. A challenge directed to an expired compound patent would have little value.

Potential competitors include established injectable manufacturers, contract manufacturers, specialty generic companies, and hospital-focused suppliers. The most credible entrants are companies with:

• FDA-inspected sterile injectable facilities
• Access to qualified glass, elastomer, and polymer components
• Cold-chain distribution capability
• Experience with anesthesia and critical-care products
• Existing hospital purchasing contracts
• Capacity to manage recalls and supply interruptions

What patent litigation and settlement risks affect rocuronium bromide?

Patent litigation risk is likely to center on a new formulation, prefilled syringe, ready-to-use bag, or manufacturing process rather than on the basic injectable composition. An innovator could assert claims covering a narrow combination of concentration, buffer, container, and stability condition.

Settlement risk is correspondingly limited unless a new entrant obtains a patent around a commercially valuable presentation. A typical ANDA settlement analysis should review:

• Paragraph IV notice letters
• 30-month stays under the Hatch-Waxman framework
• District-court docket activity
• Patent Trial and Appeal Board proceedings
• Any authorized-generic arrangements
• Launch dates and supply restrictions in settlement terms

No biosimilar litigation applies because rocuronium bromide is not a biologic. The competitive dispute is a conventional generic-drug and sterile-manufacturing matter.

What commercial opportunities exist for rocuronium bromide excipients?

Ready-to-use syringes

Prefilled syringes could reduce dose preparation, vial waste, and medication-selection errors. The commercial value is highest in emergency departments, operating rooms, intensive-care units, and ambulatory surgery centers.

The principal development risks are syringe-material compatibility, extractables and leachables, plunger performance, sterilization, labeling space, and higher unit cost.

Premixed infusion bags

A diluted rocuronium presentation could support continuous infusion protocols and reduce pharmacy compounding. It would require robust in-use stability data, clear concentration labeling, and compatibility with common administration systems.

A premixed bag is more likely to gain hospital formulary preference when it reduces preparation time or improves shortage resilience.

Room-temperature-stable products

The reference labeling uses refrigerated storage, which creates distribution and operating-room inventory burdens.[1] A formulation or packaging system that extends controlled room-temperature storage could have meaningful value.

The claim must be supported by real-time and accelerated stability data. The commercial benefit depends on the duration achieved, permitted temperature range, and whether the improvement applies to transport, pharmacy storage, or the entire labeled shelf life.

Pediatric and low-volume presentations

Smaller vial sizes or lower-volume prefilled syringes could reduce waste in pediatric and ambulatory settings. The opportunity is operational rather than pharmacological. Product design should account for dosing errors, visibility of the concentration, and compatibility with needleless systems.

Global-market formulations

A low-excipient formulation can simplify registration across jurisdictions. Differences in permitted preservatives, packaging standards, sterilization expectations, and labeling requirements still require market-specific development. A formulation based on water for injection and an acetate pH-control system may offer a relatively straightforward regulatory platform compared with a complex lipid, polymer, or depot system.

How strong is the rocuronium bromide patent estate?

The patent estate is weak around the mature active ingredient and stronger only where a supplier creates a technically differentiated product.

Asset type	Relative strength	Reason
Basic rocuronium composition	Low	Mature compound with long-established public use
Standard aqueous injection	Low	Conventional sterile formulation architecture
Acetate-buffered formulation alone	Low to moderate	Likely constrained by known reference formulation and prior art
Room-temperature-stable formulation	Moderate	Depends on unexpected stability data and claim specificity
Prefilled syringe system	Moderate	Packaging and compatibility claims may be narrower but commercially relevant
Premixed infusion bag	Moderate	Potential value from in-use stability and administration claims
Manufacturing process	Moderate	Stronger if it solves impurity, sterilization, or yield problems
Hospital workflow presentation	Moderate	Patent value depends on technical implementation, not labeling alone

The best business case is usually a combined product strategy: a robust formulation, a differentiated container, a clear hospital-use advantage, and manufacturing cost below the contracting threshold.

What generic launch risks exist for rocuronium bromide?

Generic launch risk is driven by execution rather than basic patent expiry.

Key risks include:

• FDA complete-response letters related to sterile assurance or container closure
• Visible or subvisible particulate failures
• Extractables and leachables from syringes and elastomers
• Cold-chain excursions
• Limited supply of sterile manufacturing slots
• Component shortages
• Hospital price compression
• Product recalls affecting injectable portfolios
• Difficulty securing a second qualified manufacturing site
• Low margin at contract-award volumes

A supplier should prioritize dual sourcing of critical components and establish validated transport conditions. Rocuronium is often purchased alongside other anesthesia and critical-care injectables, so a broader portfolio can improve contracting leverage.

How does rocuronium bromide compare with competing neuromuscular blockers?

Product	Competitive position	Excipient opportunity
Rocuronium bromide	Widely used nondepolarizing blocker with established generic supply	RTU syringe, premix, stability, shortage-resilient supply
Vecuronium bromide	Another aminosteroidal blocker, often requiring reconstitution depending on presentation	Reconstitution-free presentation and reduced preparation burden
Succinylcholine chloride	Depolarizing blocker with different clinical profile and storage considerations	Stability, cold-chain, and rapid-use packaging
Cisatracurium besylate	Benzylisoquinolinium blocker with distinct degradation and administration profile	Infusion stability and ready-to-use systems
Sugammadex	Reversal agent rather than competing blocker	Combination procurement and operating-room workflow strategy

Rocuronium has a stronger opportunity for hospital workflow products than for novel excipient science. A well-designed presentation can compete on medication safety, preparation time, and supply continuity even when the active ingredient is interchangeable.

What revenue exposure and licensing opportunities exist?

Revenue exposure is concentrated in hospital and institutional procurement. Unit prices are typically constrained by generic competition, while annual revenue depends on contract access, supply reliability, and portfolio breadth.

Licensing opportunities include:

• A formulation platform for room-temperature stability
• A prefilled-syringe technology
• A polymer container with demonstrated compatibility
• A sterile manufacturing process that improves yield or reduces impurities
• Regional commercialization rights for anesthesia injectables
• Co-development with a contract development and manufacturing organization

An excipient supplier could license a validated buffer or packaging system, but a standard acetate formulation alone is unlikely to command substantial royalty economics. The licensable asset needs a documented performance advantage and a regulatory package that shortens development time.

Key Takeaways

1. Rocuronium bromide is a mature generic injectable, not a biologic, so biosimilar risk is irrelevant and active-ingredient exclusivity is no longer the central issue.
2. The reference formulation is a simple acidic aqueous injection using water for injection and acetate-based pH control.
3. The strongest excipient opportunities involve stability, packaging compatibility, ready-to-use delivery, and reduced cold-chain dependence.
4. Standard buffer substitutions are unlikely to support strong patent protection without unexpected technical results.
5. Prefilled syringes, premixed infusion bags, and smaller-volume presentations offer the clearest commercial differentiation.
6. FDA approval risk is concentrated in sterile manufacturing, particulate control, container compatibility, and stability.
7. Hospital contracts, reliable supply, and manufacturing redundancy will usually matter more than broad patent exclusivity.

FAQs

Can rocuronium bromide be formulated without sodium acetate?

Yes. A sponsor could evaluate another buffer or pH-adjusting system, provided the formulation meets stability, sterility, compatibility, osmolality, and regulatory requirements. The change would need a clear technical rationale and comparative product data.

Is a preservative necessary in rocuronium bromide injection?

No. Preservative-free single-dose packaging is a commercially established strategy for parenteral products. A multi-dose product would require a different antimicrobial-preservation and in-use stability assessment.

Can rocuronium bromide be sold in a prefilled syringe?

Yes. A prefilled syringe would require evaluation of syringe materials, plunger and stopper performance, extractables and leachables, sterility, dose accuracy, and shelf-life stability.

Does rocuronium bromide require refrigerated storage?

Many labeled products use refrigerated storage, with defined allowances for room-temperature exposure depending on the manufacturer and presentation.[1,2] A product with longer controlled room-temperature stability could create a meaningful logistics advantage.

Can an excipient supplier obtain patent protection for a rocuronium formulation?

Potentially, but protection is more credible when the formulation produces an unexpected result, such as improved room-temperature stability, reduced particulates, or superior compatibility with a delivery device. Conventional buffering or routine excipient replacement is less likely to support broad claims.

References

1. U.S. Food and Drug Administration. (2023). Zemuron (rocuronium bromide) injection: Prescribing information. FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/

2. National Library of Medicine. (2024). DailyMed: Rocuronium bromide injection product labeling. DailyMed. https://dailymed.nlm.nih.gov/dailymed/

3. U.S. Food and Drug Administration. (2016). Guidance for industry: ANDAs for certain highly purified synthetic peptides. FDA. https://www.fda.gov/regulatory-information

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. FDA. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book